Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry
Hum, Ryan Malcolm , Lamb, Janine A. , Oldroyd, Alexander , Wang, Guochun , Wedderburn, Lucy R, Diederichsen, Louise Pyndt , Schmidt, Jens , Danieli, Maria Giovanna , Oakley, Paula, Griger, Zoltán , Phuong, Thuy Nguyen Thi , Kodishala, Chanakya , Mercado, Mónica Vázquez-Del , Andersson, Helena , Paepe, Boél De , Maurer, Britta , McCann, Liza , Pipitone, Nicolò , McHugh, Neil , New, Robert P, Ollier, William , Krogh, Niels Steen , Lundberg, Ingrid E. , Chinoy, Hector , Registry, MYONET, D’hose, Sophie, Lu, Xin , Tian, Xiaolan , Pleštilová, Lenka, Barochová, Tereza, Kubínová, Kateřina , Gelardi, Chiara, Paladini, Alberto , Piga, Mario Andrea , Jara, Luis J. , Cruz‐Reyes, Claudia , Andrade-Ortega, Lilia, Medrano-Ramírez, Gabriel , Salazar-Páramo, Mario , Chavarría-Ávila, Efrain , Aguilar-Vázquez, Andrea, Anda, Jesús-Aureliano Robles-De , Molberg, Øyvind , Dastmalchi, Maryam, Notarnicola, Antonella , Gheorghe, Karina, Liden, Maria, Hanna, Balsam , Jalal, Awat, Hellström, Helena, Martineus, Jehns Christian, New, Paul, Platt, Hazel, Ahmed, Yasmeen , Armstrong, Raymond, Bernstein, Robert, Black, Carol M., Butler, Robin, Carty, John , Chattopadhyay, Chandra, Chelliah, E G, Clarke, Fiona, Dawes, P. T., Devlin, Joseph, Edwards, Christopher, Emery, Paul , Fordham, J. L. A., Fraser, Alexander, Gaston, Hill, Gordon, Patrick , Griffiths, Bridget , Gunawardena, Harsha , Hall, Frances, Hanna, Michael G. , Harrison, Beverley, Hay, Elaine M. , Hilton‐Jones, David, Horden, Lesley, Jones, Adrian, Kamath, Sanjeet, Kennedy, Thomas J. , Klimiuk, P S, Knights, Sally, Lambert, John, Laxminarayan, Ramasharan, Lecky, Bryan, Marks, Jeffrey M., Martin, Michael F., McGonagle, Dennis , McHugh, Neil, McKenna, Francis, McLaren, John, McMahon, Michael , McRorie, Euan , Merry, P, Miller, James , Nicholls, Anne, Ong, Voon , Over, K. E., Packham, John, Pipitone, Nicolo, Plant, Michael, Pountain, G., Pullar, T, Roberts, Mark, Scott, David A. , Shadforth, M F, Sheeran, Thomas, Srinivasan, Arul, Swinson, David, Teh, Lee‐Suan , Webley, M, Winer, Jonathan M., Wedderburn, Lucy R. , Lilleker, James B , Lamb, Janine A , Oldroyd, Alexander G S , Wedderburn, Lucy R , Griger, Zoltan , Nguyen Thi Phuong, Thuy , Kodishala, Chanakya , Vazquez-Del Mercado, Monica , De Paepe, Boel , McHugh, Neil , Vencovsky, Jiri , Lundberg, Ingrid E , Chinoy, Hector , McCann, Liza J , Bleecker, Jan De , Vencovský, Jiří , Registry, MYONET, Mann, H. , Kryštůfková, Olga , Klein, Martin , Saavedra, Miguel A , Lastra, Olga Lidia Vera , Satoh, Minoru , Petri, Marcelo H. , Rönnelid, Johan , Lan, Nguyễn Thị Ngọc , Padyukov, Leonid , Rothwell, Simon W. , Bernstein, Robert, Bowman, Simon , Bruce, Ian N , Carty, John, Denton, Christopher P. , Edwards, Christopher, Fordham, John, Isaacs, John Dudley , Isenberg, David , Kitas, George D. , Lanyon, Peter , Luqmani, Raashid Ahmed , Machado, Pedro , Marks, Jeffrey, Martin, Michael, McHugh, Neil, Miles, Sarah, Nixon, Jennifer, Ong, Voon, Packham, John, Pipitone, Nicolo, Sanders, Paul W. , Williams, Brian, Winer, Jonathan

Mayo Clinic

Rheumatology | September 11, 2023 | Volume: 63 | Issue: 8 | Pages: 2093-2100

10.1093/rheumatology/kead481 | PMID 37698987 Get It

Abstract Objectives To compare clinical characteristics, including the frequency of cutaneous, extramuscular manifestations and malignancy, between adults with anti-synthetase syndrome (ASyS) and DM. Methods Using data regarding adults from the MYONET registry, a cohort of DM patients with anti-Mi2/-TIF1γ/-NXP2/-SAE/-MDA5 autoantibodies, and a cohort of ASyS patients with anti-tRNA synthetase autoantibodies (anti-Jo1/-PL7/-PL12/-OJ/-EJ/-Zo/-KS) were identified. Patients with DM sine dermatitis or with discordant dual autoantibody specificities were excluded. Sub-cohorts of patients with ASyS with or without skin involvement were defined based on presence of DM-type rashes (heliotrope rash, Gottron’s papules/sign, violaceous rash, shawl sign, V-sign, erythroderma, and/or periorbital rash). Results In total 1054 patients were included (DM, n = 405; ASyS, n = 649). In the ASyS cohort, 31% (n = 203) had DM-type skin involvement (ASyS-DMskin). A higher frequency of extramuscular manifestations, including Mechanic’s hands, Raynaud’s phenomenon, arthritis, interstitial lung disease and cardiac involvement differentiated ASyS-DMskin from DM (all P < 0.001), whereas higher frequency of any of four DM-type rashes—heliotrope rash (n = 248, 61% vs n = 90, 44%), violaceous rash (n = 166, 41% vs n = 57, 9%), V-sign (n = 124, 31% vs n = 28, 4%), and shawl sign (n = 133, 33% vs n = 18, 3%)—differentiated DM from ASyS-DMskin (all P < 0.005). Cancer-associated myositis (CAM) was more frequent in DM (n = 67, 17%) compared with ASyS (n = 21, 3%) and ASyS-DMskin (n = 7, 3%) cohorts (both P < 0.001). Conclusion DM-type rashes are frequent in patients with ASyS; however, distinct clinical manifestations differentiate these patients from classical DM. Skin involvement in ASyS does not necessitate increased malignancy surveillance. These findings will inform future ASyS classification criteria and patient management.
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
Goodwin, Pamela J. , Chen, Bingshu E. , Gelmon, Karen A. , Whelan, Timothy J. , Ennis, Marguerite , Ligibel, Jennifer A. , Hershman, Dawn L. , Mayer, Ingrid A. , Hobday, Timothy J. , Bliss, Judith M. , Rastogi, Priya , Thompson, Alastair M. , Stos, Paul M., Shepherd, Lois E. , Parulekar, Wendy R. , Mayer, IA , Ligibel, Jennifer A , Hershman, Dawn L , Hobday, Timothy J , Bliss, Judith , Rastogi, Priya , Rea, Daniel W , Shepherd, LE , Parulekar, Wendy R , Ennis, Marguerite , Chen, Bingshu E , Gelmon, Karen A , Lemieux, Julie , Rabaglio, Manuela , Rea, Daniel , Stambolic, Vuk , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | September 11, 2023 | Volume: 41 | Issue: 35 | Pages: 5356-5362

10.1200/jco.23.00296 | PMID 37695982 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin ( v placebo) did not affect invasive disease-free or overall survival. Here, we report metformin effects on the risk of new cancer. Between 2010 and 2013, 3,649 patients with breast cancer younger than 75 years without diabetes with high-risk T1-3, N0-3 M0 breast cancer (any estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2) were randomly assigned to metformin 850 mg orally twice a day or placebo twice a day for 5 years. New primary invasive cancers (outside the ipsilateral breast) developing as a first event were identified. Time to events was described by the competing risks method; two-sided likelihood ratio tests adjusting for age, BMI, smoking, and alcohol intake were used to compare metformin versus placebo arms. A total of 184 patients developed new invasive cancers: 102 metformin and 82 placebo, hazard ratio (HR), 1.25; 95% CI, 0.94 to 1.68; P = .13. These included 48 contralateral invasive breast cancers (27 metformin v 21 placebo), HR, 1.29; 95% CI, 0.72 to 2.27; P = .40 and 136 new nonbreast primary cancers (75 metformin v 61 placebo), HR, 1.24; 95% CI, 0.88 to 1.74; P = .21. Metformin did not reduce the risk of new cancer development in these nondiabetic patients with breast cancer.
What's new in benign lung tumours?
Boland, Jennifer M.

Mayo Clinic

Histopathology | September 11, 2023 | Volume: 84 | Issue: 1 | Pages: 124-135

10.1111/his.15037 | PMID 37691383 Get It

While lung cancer is one of the most common malignancies routinely encountered by pathologists, benign pulmonary neoplasms are quite rare. However, it is important for pathologists to be familiar with the typical diagnostic features of benign lung tumors to avoid confusing them with malignant morphological mimics. There have also been intriguing discoveries in the genetics of benign pulmonary neoplasms in the past decade. This review will cover several of the most common benign lung tumors, including the diagnostic categories of pulmonary adenomas, bronchial papillomas, and benign mesenchymal tumors, with discussion of the current classification, differential diagnosis, and current knowledge regarding genetic drivers.
Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease
Huang, Yannan , Sompii‐Montgomery, Laura, Patti, Jessica, Pickering, Alex, Yasin, Shima , Gao, Denny , Abdul‐Aziz, Rabheh , Behrens, Edward M. , Co, Dominic O. , Collins, Kathleen , Eberhard, B. Anne, Friedman, Monica, Graham, T. Brent , Hahn, Timothy , Hersh, Aimee O. , Hobday, Patricia M. , Holland, Michael J., Huggins, Jennifer , Lu, Pai‐Yue, Mannion, Melissa L. , Manos, Cynthia K., Neely, Jessica , Ramirez, Andrea, Reinhardt, Adam, Riskalla, Mona , Santiago, L E, Ting, Tracy V. , Grom, Alexei A. , Towe, C. , Gao, Denny , Canna, Scott , Hersh, Aimee O , Mannion, Melissa L , Neely, Jessica , Schulert, Grant S , Behrens, Edward M , Do, Thuy, Baker, Elizabeth K. , Clark, Matthew, Collins, Kathleen , Holland, Michael J., Onel, Karen , Orandi, Amir B. , Stoll, Matthew Laurence

Mayo Clinic

Arthritis Care & Research | September 11, 2023 | Volume: 76 | Issue: 3 | Pages: 328-339

10.1002/acr.25234 | PMID 37691306 Get It

Objective Systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD) is a life‐threatening disease complication. Key questions remain regarding clinical course and optimal treatment approaches. The objectives of the study were to detail management strategies after SJIA‐LD detection, characterize overall disease courses, and measure long‐term outcomes. Methods This was a prospective cohort study. Clinical data were abstracted from the electronic medical record, including current clinical status and changes since diagnosis. Serum biomarkers were determined and correlated with presence of LD. Results We enrolled 41 patients with SJIA‐LD, 85% with at least one episode of macrophage activation syndrome and 41% with adverse reactions to a biologic. Although 93% of patients were alive at last follow‐up (median 2.9 years), 37% progressed to requiring chronic oxygen or other ventilator support, and 65% of patients had abnormal overnight oximetry studies, which changed over time. Eighty‐four percent of patients carried the HLA‐DRB1*15 haplotype, significantly more than patients without LD. Patients with SJIA‐LD also showed markedly elevated serum interleukin‐18 (IL‐18), variable C‐X‐C motif chemokine ligand 9 (CXCL9), and significantly elevated matrix metalloproteinase 7. Treatment strategies showed variable use of anti–IL‐1/6 biologics and addition of other immunomodulatory treatments and lung‐directed therapies. We found a broad range of current clinical status independent of time from diagnosis or continued biologic treatment. Multidomain measures of change showed imaging features were the least likely to improve with time. Conclusion Patients with SJIA‐LD had highly varied courses, with lower mortality than previously reported but frequent hypoxia and requirement for respiratory support. Treatment strategies were highly varied, highlighting an urgent need for focused clinical trials.
P13.02.A APPLICATION OF NOVEL PACS-BASED INFORMATICS PLATFORM TO IDENTIFY IMAGING BASED PREDICTORS OF CDKN2A ALLELIC STATUS IN GLIOBLASTOMAS
Tillmanns, Niklas , Lost, Jan , Vasandani, Sagar, Vetsa, Shaurey , Marianayagam, Neelan J. , Yalçın, Kendal , Erson-Omay, Zeynep, Reppert, Marc von , Merkaj, Sara , Ramakrishnan, Divya , Avesta, Arman , Santo, Irene Dixe de Oliveira , Bousabarah, Khaled , Turowski, Bernd , Aboian, Mariam , Moliterno, Jennifer , Aboian, Mariam S , Dixe de Oliveira Santo, Irene , Tabor, Jacek , Yalcin, K, Erson-Omay, Zeynep , Jekel, Leon , Jin, Lei , Hüttner, Anita , Ikuta, Ichiro , Lin, MingDe , Aneja, Sanjay

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii100-ii101

10.1093/neuonc/noad137.336 Get It

Abstract BACKGROUND Gliomas with CDKN2A mutations are known to have worse prognosis but imaging features of these gliomas are unknown. Our goal is to identify CDKN2A specific qualitative imaging biomarkers in glioblastomas using a new informatics workflow that enables rapid analysis of qualitative imaging features with Visually AcceSAble Rembrandtr Images (VASARI) for large datasets in PACS. Gliomas with CDKN2A mutations are known to have worse prognosis but imaging features of these gliomas are unknown. Our goal is to identify CDKN2A specific qualitative imaging biomarkers in glioblastomas using a new informatics workflow that enables rapid analysis of qualitative imaging features withVisually AcceSAble Rembrandtr Images (VASARI) for large datasets in PACS. MATERIAL AND METHODS Sixty nine patients undergoing GBM resection with CDKN2A status determined by whole-exome sequencing were included. GBMs on magnetic resonance images were automatically 3D segmented using deep learning algorithmsincorporated within PACS. VASARI features were assessed using FHIR forms integrated within PACS. RESULTS GBMs without CDKN2A alterations were significantly larger (64% vs. 30%, p=0.007) compared to tumors with homozygous deletion (HOMDEL) and heterozygous loss (HETLOSS). Lesions larger than 8 cm were four times more likely to have no CDKN2A alteration (OR: 4.3; 95% CI:1.5-12.1; p<0.001). The pial invasion was predictive of HOMDEL (OR: 8.1, 95% CI: 1.8-53.2; p<0.012) as tumors with pial invasion were eight times more likely to be HOMDEL, even after adjusting for deep white matter and subependymal invasion. CONCLUSION We developed a novel integrated PACS informatics platform for the assessment of GBM molecular subtypes and show that tumors with HOMDEL are more likely to have radiographic evidence of pial invasion and less likely to have deep white matter invasion or subependymal invasion. These imaging features may allow noninvasive identification of CDKN2A allele status.
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers
Cavalcante, Ludimila , Deshmukh, Sachin Kumar , Ribeiro, Jennifer R. , Carneiro, Benedito A. , Dizon, Don S. , Mattox, Tyler , Wu, Sharon , Xiu, Joanne , Nabhan, Chadi , Oberley, Matthew , Nabhan, Chadi , Antonarakis, Emmanuel S , Angara, Kartik , Walker, Phillip , Oberley, Matthew J. , Huang, Haojie , Antonarakis, Emmanuel S.

Mayo Clinic

JCO Precision Oncology | September 7, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.23.00088 | PMID 37677121 Get It

SPOP mutations drive opposing molecular and immune landscapes in prostate and endometrial cancers, suggesting tailored therapies
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023
Bevers, Therese B. , Niell, Bethany L. , Bonaccio, Ermelinda, Camp, Melissa , Chikarmane, Sona A. , Eghtedari, Mohammad , Flanagan, Meghan R. , Hawley, Jeffrey , Helvie, Mark A. , Hodgkiss, Linda, Hoyt, Tamarya L., Ivanovich, Jennifer , Kulkarni, Swati , Lancaster, Rachael, Mauer, Caitlin , Pearlman, Mark D. , Philpotts, Liane E. , Plichta, Jennifer K. , Shakeri, Shadi Aminololama, Smith, Mary Lou , Streibert, Clarie L., Strigel, Roberta M. , Tumyan, Lusine , Winkler, Nicole , Wolverton, Dulcy , Bergman, Mary Anne, Stehman, Katie, Plichta, Jennifer K , Baker, Jennifer L. , Bennett, Debbie Lee , Conant, Emily F. , Jochelson, Maxine S. , Maxwell, Jessica, Patel, Bhavika , Plecha, Donna , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 900-909

10.6004/jnccn.2023.0046 | PMID 37673117 Get It

The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.
The first reported use of red blood cell exchange to treat hemoglobin Evans with secondary methemoglobinemia
Adamski, Jill , Kinard, Theresa N. , Ertz-Archambault, Natalie , Lu, Qun , Gray, Kristin , Su, Leon , Padrnos, Leslie , Williams, Lance A , Herrick, Jennifer L.

Mayo Clinic

Journal of Clinical Apheresis | September 4, 2023 | Volume: 38 | Issue: 6 | Pages: 755-759

10.1002/jca.22086 | PMID 37665037 Get It

Abstract This manuscript describes a novel approach for treating patients with long‐term sequelae from hemoglobin Evans (Hb Evans). After instituting conservative therapies for approximately 2 years, our patient's symptoms continually worsened. Therefore, we performed red blood cell exchange (RBCx) to reduce his Hb Evans percentage and his co‐existing elevation of methemoglobin. Our assumptions of clinical benefit were based on our collective experience performing RBCx for patients with sickle cell disease. After the first exchange, pre‐ and post‐laboratory results supported our approach and the patient experienced marked improvement in his clinical signs and symptoms. This report provides preliminary proof of principle for the use of RBCx to treat Hb Evans and other non‐Hb S hemoglobinopathies.
Classification and Predictors of Right Ventricular Functional Recovery in Pulmonary Arterial Hypertension
Rischard, Franz , Bernardo, Roberto J. , Vanderpool, Rebecca , Kwon, Deborah , Acharya, Tushar , Park, Margaret , Katrynuik, Austin, Insel, Michael , Kubba, Saad , Badagliacca, Roberto , Larive, A. Brett, Naeije, Robert , Garcia, Joe G. N. , Beck, Gerald J. , Erzurum, Serpil C. , Hill, Nicholas S. , Wilcox, Jennifer , Rischard, Franz P , Vanderpool, Rebecca R , Kwon, Deborah H , Park, Margaret M , Frantz, Robert P , Hemnes, Anna , Hill, Nicholas S , Horn, Evelyn M , Leopold, Jane A , Rosenzweig, Erika B , Tang, W H Wilson , Wilcox, Jennifer D , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rosenzweig, Erika B. , Tang, W.H. Wilson

Mayo Clinic

Circulation: Heart Failure | September 4, 2023 | Volume: 16 | Issue: 10 | Pages: No page available

10.1161/circheartfailure.123.010555 | PMID 37664964 Get It

Background: Normative changes in right ventricular (RV) structure and function have not been characterized in the context of treatment-associated functional recovery (RV functional recovery [RVFnRec]). The aim of this study is to assess the clinical relevance of a proposed RVFnRec definition. Methods: We evaluated 63 incident patients with pulmonary arterial hypertension by right heart catheterization and cardiac magnetic resonance imaging at diagnosis and cardiac magnetic resonance imaging and invasive cardiopulmonary exercise testing following treatment (≈11 months). Sex, age, ethnicity matched healthy control subjects (n=62) with 1-time cardiac magnetic resonance imaging and noninvasive cardiopulmonary exercise testing were recruited from the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) project. We examined therapeutic cardiac magnetic resonance imaging changes relative to the evidence-based peak oxygen consumption (VO 2peak )>15 mL/(kg·min) to define RVFnRec by receiver operating curve analysis. Afterload was measured as mean pulmonary artery pressure, resistance, compliance, and elastance. Results: A drop in RV end-diastolic volume of −15 mL best defined RVFnRec (area under the curve, 0.87; P =0.0001) and neared upper 95% CI RV end-diastolic volume of controls. This cutoff was met by 22 out of 63 (35%) patients which was reinforced by freedom from clinical worsening, RVFnRec 1 out of 21 (5%) versus no RVFnRec 17 out of 42, 40% (log-rank P =0.006). A therapy-associated increase of 0.8 mL/mm Hg in compliance had the best predictive value of RVFnRec (area under the curve, 0.76; [95% CI, 0.64–0.88]; P =0.001). RVFnRec patients had greater increases in stroke volume, and cardiac output at exercise. Conclusions: RVFnRec defined by RV end-diastolic volume therapeutic decrease of −15 mL predicts exercise capacity, freedom from clinical worsening, and nears normalization. A therapeutic improvement of compliance is superior to other measures of afterload in predicting RVFnRec. RVFnRec is also associated with increased RV output reserve at exercise.
Prognostic and Diagnostic Utility of Serum Biomarkers in Pediatric Traumatic Brain Injury
Pareja, Jennifer C. Muñoz , Vaccari, Juan Pablo de Rivero , Chavez, Maria Mateo , Kerrigan, Maria, Pringle, Charlene , Guthrie, Kourtney, Swaby, Kathryn, Coto, Jennifer , Avery, K. Leslie , Ghosh, Suman , Dhanashree, Rajderkar, Shanmugham, Prashanth, Lautenslager, Lauren A. , Faulkenberry, Shannon, Zabala, María C. Pareja , Fakhri, Nora Al, Loor-Torres, Ricardo , Governale, Lance S., Blatt, Jason E. , Gober, Joslyn , Perez, Paula Karina, O’Phelan, Kristine , Dietrich, W. Dalton , Mateo Chavez, Maria B , Pringle, Charlene P , de Rivero Vaccari, Juan Pablo , Kobeissy, Firas , Solano, Juan, McCrea, Heather J. , Thorson, Chad M. , Keane, Robert W. , Wang, Kevin

Mayo Clinic

Journal of Neurotrauma | August 30, 2023 | Volume: 41 | Issue: 1-2 | Pages: 106-122

10.1089/neu.2023.0039 | PMID 37646421 Get It

Traumatic brain injury (TBI) remains a major cause of morbidity and death among the pediatric population. Timely diagnosis, however, remains a complex task because of the lack of standardized methods that permit its accurate identification. The aim of this study was to determine whether serum levels of brain injury biomarkers can be used as a diagnostic and prognostic tool in this pathology. This prospective, observational study collected and analyzed the serum concentration of neuronal injury biomarkers at enrollment, 24h and 48h post-injury, in 34 children ages 0–18 with pTBI and 19 healthy controls (HC). Biomarkers included glial fibrillary acidic protein (GFAP), neurofilament protein L (NfL), ubiquitin-C-terminal hydrolase (UCH-L1), S-100B, tau and tau phosphorylated at threonine 181 (p-tau181). Subjects were stratified by admission Glasgow Coma Scale score into two categories: a combined mild/moderate (GCS 9–15) and severe (GCS 3–8). Glasgow Outcome Scale-Extended (GOS-E) Peds was dichotomized into favorable (≤4) and unfavorable (≥5) and outcomes. Data were analyzed utilizing Prism 9 and R statistical software. The findings were as follows: 15 patients were stratified as severe TBI and 19 as mild/moderate per GCS. All biomarkers measured at enrollment were elevated compared with HC. Serum levels for all biomarkers were significantly higher in the severe TBI group compared with HC at 0, 24, and 48h. The GFAP, tau S100B, and p-tau181 had the ability to differentiate TBI severity in the mild/moderate group when measured at 0h post-injury. Tau serum levels were increased in the mild/moderate group at 24h. In addition, NfL and p-tau181 showed increased serum levels at 48h in the aforementioned GCS category. Individual biomarker performance on predicting unfavorable outcomes was measured at 0, 24, and 48h across different GOS-E Peds time points, which was significant for p-tau181 at 0h at all time points, UCH-L1 at 0h at 6–9 months and 12 months, GFAP at 48h at 12 months, NfL at 0h at 12 months, tau at 0h at 12 months and S100B at 0h at 12 months. We concluded that TBI leads to increased serum neuronal injury biomarkers during the first 0–48h post-injury. A biomarker panel measuring these proteins could aid in the early diagnosis of mild to moderate pTBI and may predict neurological outcomes across the injury spectrum.